UK Markets closed

BRAIN Biotech AG (0RFI.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
7.600.00 (0.00%)
At close: 12:43PM BST
Full screen
Previous close7.60
Open7.60
Bid0.00 x 0
Ask0.00 x 0
Day's range7.60 - 7.60
52-week range7.60 - 7.60
Volume14,602
Avg. volumeN/A
Market cap137.495M
Beta (5Y monthly)1.49
PE ratio (TTM)N/A
EPS (TTM)-0.33
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • EQS Group

    BRAIN Biotech AG: Successful Genome Editing in Mammalian Cells with BRAIN-Metagenome-Cas (BMC), BRAIN-Engineered-Cas (BEC)

    DGAP-News: BRAIN Biotech AG / Key word(s): Miscellaneous04.04.2022 / 10:40 The issuer is solely responsible for the content of this announcement.Successful Genome Editing in Mammalian Cells with BRAIN-Metagenome-Cas (BMC), BRAIN-Engineered-Cas (BEC) Major milestone achieved: genome-editing in mammalian cell lines Potential to target very large addressable markets BEC, BMC well suited for different application fieldsZwingenberg, Germany, April, 4th 2022 - BRAIN Biotech AG has achieved a major mil

  • EQS Group

    BRAIN Biotech AG: Successful Genome Editing Activity in Mammalian Cells with BRAIN-Metagenome-Cas (BMC), BRAIN-Engineered-Cas (BEC)

    BRAIN Biotech AG / Key word(s): MiscellaneousBRAIN Biotech AG: Successful Genome Editing Activity in Mammalian Cells with BRAIN-Metagenome-Cas (BMC), BRAIN-Engineered-Cas (BEC) 04-Apr-2022 / 10:31 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.Successful Genome Editing Activity in Mammalian Cells with BRAIN-Metagenome-Cas (B

  • EQS Group

    BRAIN Biotech AG: Resolutions of the Annual General Meeting for the Fiscal Year 2020/2021 of BRAIN Biotech AG

    DGAP-News: BRAIN Biotech AG / Key word(s): AGM/EGM09.03.2022 / 16:00 The issuer is solely responsible for the content of this announcement.Resolutions of the Annual General Meeting for the Fiscal Year 2020/2021 of BRAIN Biotech AG Executive Board and Supervisory Board discharged by a large majority Shareholder majority approves capital reserve advance resolutions Positive outlook for the new fiscal yearZwingenberg, Germany, 9 March 2022 - At today's Annual General Meeting of BRAIN Biotech AG, th